1. Maixner F, Krause-Kyora B, Turaev D, Herbig A, Hoopmann MR, Hallows JL, Kusebauch U, Vigl EE, Malfertheiner P, Megraud F, O'Sullivan N, Cipollini G, Coia V, Samadelli M, Engstrand L, Linz B, Moritz RL, Grimm R, Krause J4, Nebel A, Moodley Y, Rattei T, Zink A. The 5300-year-old Helicobacter pylori genome of the Iceman. Science. 2016;351(6269):162-5. doi: 10.1126/science.aad2545
2. Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomed J. 2016;39:14-23. doi: 10.1016/j.bj.2015.06.002
3. Schistosomes, liver flukes and Helicobacter pylori IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.
4. Маев И.В., Бакулин И.Г., Курилович С.А., Бакулина Н.В., Андреев Н.Г., Голубев Н.Н. Helicobacter pylori и экстрагастродуоденальные заболевания: доказанные факты и предположения. Доказательная гастроэнтерология. 2018;7(3):45-59 [Maev IV, Bakulin IG, Kurilovich SA, Bakulina NV, Andreev NG, Golubev NN. Helicobacter pylori and extragastroduodenal diseases: the proven facts and assumptions. Dokazatel'naya Gastroenterologiya. 2018;7(3):45-59 (In Russ.)]. doi: 10.17116/dokgastro2018703145
5. Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter. 2015;20(Suppl 1):40-6. doi: 10.1111/hel.12256
6. Kountouras J, Polyzos SA, Katsinelos P, Zeglinas C, Artemaki F, Tzivras D, Vardaka E, Gavalas E, Romiopoulos I, Simeonidou C, Grigoriadis N, Kountouras C, Dardiotis E, Deretzi G. Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. Int J Cardiol. 2017;229:17-8. doi: 10.1016/j.ijcard.2016.11.265
7. Wang XL, Zeng J, Yang Y, Xiong Y, Zhang ZH, Qiu M, Yan X, Sun XY, Tuo QZ, Liu R, Wang JZ. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3β. J Alzheimers Dis. 2015;43:153-65. doi: 10.3233/JAD-140198
8. Ricci V, Romano M, Boquet P. Molecular cross-talk between Helicobacter pylori and human gastric mucosa. World J Gastroenterol. 2011;17(11):1383-99. doi: 10.3748/wjg.v17.i11.1383
9. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-67. doi: 10.1136/gutjnl-2015-309252
10. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelho LG, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh KL, Wong BC, Krabshuis J, Le Mair A, World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20:299-304.
11. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. doi: 10.1136/gutjnl-2016-312288
12. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Дехнич Н.Н., Козлов Р.С., Кляритская И.Л., Корочанская Н.В., Курилович С.А., Осипенко М.Ф., Симаненков В.И., Ткачев А.В., Хлынов И.Б., Цуканов В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70 [Ivashkin VT, Mayev IV, Lapina TL, Sheptulin AA, Trukhmanov AS, Baranskaya YeK, Abdulkhakov RA, Alekseyeva OP, Alekseyenko SA, Dekhnich NN, Kozlov RS, Klyaritskaya IL, Korochanskaya N.V, Kurilovich SA, Osipenko MF, Simanenkov VI, Tkachev AV, Khlynov IB, Tsukanov VV. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2018;28(1):55-70 (In Russ.)].
13. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
14. Graham DY. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut. 2017;66:2043-6. doi: 10.1136/gutjnl-2017-314744
15. Zagari RM, Rabitti S, Eusebi LH, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest. 2018;48:e12857. doi: 10.1111/eci.12857
16. Бакулина Н.В., Симаненков В.И., Бакулин И.Г., Ильчишина Т.А. Распространенность хеликобактерной инфекции среди врачей. Экспериментальная и клиническая гастроэнтерология. 2017;12(148):20-4 [Bakulina NV, Simanenkov VI, Bakulin IG, Ilchishina TA. Prevalence of Helicobacter pylori infection among physicians. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2017;148(12):20-4 (In Russ.)].
17. Auttajaroon J, Chotivitayatarakorn P, Yamaoka Y, Vilaichone RK. CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection. Asian Pac J Cancer Prev. 2019;20(4):1243-7. doi: 10.31557/APJCP.2019.20.4.1243
18. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9 [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
19. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-40. doi: 10.5829/idosi.wasj.2014.30.mett.61
20. Boltin D, Dotan I, Birkenfeld S. Improvement in the implementation of Helicobacter pylori management guidelines among primary care physicians following a targeted educational intervention. Ann Gastroenterol. 2019;32(1):52-9. doi: 10.20524/aog.2018.0329
21. Ribaldone D, Astegiano M, Pellicano R. Helicobacter pylori eradication: poor medical compliance from East to West of the world. Scand J Gastroenterol. 2018;53:265. doi: 10.1080/00365521.2018.1433231
22. Осипенко М.Ф., Ливзан М.А., Бикбулатова Е.А. «Комплаентность» пациента как один из факторов, определяющих эффективность эрадикационной терапии. Терапевтический архив. 2014;86(2):27-31 [Osipenko MF, Livzan MA, Bikbulatova EA. Patient compliance as one of the factors determining the efficiency of eradication therapy. Therapeutic Archive. 2014;86(2):27-31 (In Russ.)].
23. O'Connor HJ. Helicobacter pylori and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits. Aliment Pharmacol Ther. 2002;16(3):487-96. doi: 10.1046/j.1365-2036.2002.01183.x
24. Бордин Д., Белоусова Н., Воробьёва Н., Зеленикин С. Язвенная болезнь: пути повышения эффективности эрадикации Helicobacter pylori. Врач. 2011;(4):43-7 [Bordin D, Belousova N, Vorob'yova N, Zelenikin S. Ulcer disease: ways to increase the efficiency of Helicobacter pylori eradication. Vrach. 2011;(4):43-7 (In Russ.)].
25. Wang CH, Liao ST, Yang J, Li CX, Yang YY, Han R, Chen DF, Lan CH. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. World J Gastroenterol. 2015;21(39):11179-84. doi: 10.3748/wjg.v21.i39.11179
26. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitorbased triple therapy regimens: a meta-analysis of randomized clinical trials. Plos One. 2013;8:e62162. doi: 10.1371/journal.pone.0062162
27. Елохина Е.В., Костенко М.Б., Ливзан М.А., Скальский С.В. Эффективность эрадикационной терапии у пациентов с язвенной болезнью, ассоциированной с Helicobacter pylori, в зависимости от генотипа лекарственного метаболизма ингибиторов протонной помпы. Экспериментальная и клиническая гастроэнтерология. 2015;115(3):31-3 [Elokhina EV, Kostenko MB, Livzan MA, Scalskiy SV. The effectiveness of eradication in patients with peptic ulcer disease associated with Helicobacter pylori, depending on the genotype of the drugmetabolism of proton pump inhibitors. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2015;115(3):31-3 (In Russ.)].
28. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868-77. doi: 10.1111/j.1365-2036.2008.03807.x
29. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90 [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
30. Graham DY, Dore MP. Update on the use of vonoprazan: a competitive acid blocker. Gastroenterology. 2018;154:462-6. doi: 10.1053/j.gastro.2018.01.018
31. Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza I, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci. 2018;63:302-11. doi: 10.1007/s10620-017-4866-6
32. Kusunoki M, Yuki M, Ishitobi H, Kobayashi Y, Nagaoka M, Takahashi Y, Fukuba N, Komazawa Y, Shizuku T, Kinoshita Y. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication. Intern Med. 2019 Feb 1. doi: 10.2169/internalmedicine.2233-18
33. Sugimoto M, Yamaoka Y. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019;9:1560. doi: 10.3389/fphar.2018.01560
34. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304
35. Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potas- sium-Competitive Acid Blocker Compared With a 7-Day PPI- Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol. 2016;111(7):949-56. doi: 10.1038/ajg.2016.182
36. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-33. doi: 10.1111/apt.13497
37. Mégraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34-42. doi: 10.1136/gutjnl-2012-302254
38. Hu Y, Zhu Y, Lu NH. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 2017;7:168. doi: 10.3389/fcimb.2017.00168
39. Pellicano R, Zagari RM, Zhang S, Saracco GM, Moss SF. Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018;64:310-21. doi: 10.23736/S1121-421X.18.02492-3
40. Бордин Д.С., Эмбутниекс Ю.В., Вологжанина Л.Г. и др. Европейский регистр Helicobacter pylori (HP-EUREG): как изменилась клиническая практика в России с 2013 по 2018 год. Терапевтический архив. 2019;91(2):16-24 [Bordin DS, Embutnieks YuV, Vologzhanina LG, et al. European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years. Therapeutic Archive. 2019;91(2):16-24 (In Russ.)]. doi: 10.26442/00403660.2019.02.000156
41. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318-27. doi: 10.1016/S1473-3099(17)30753-3
42. He X, Liao X, Li H, Xia W, Sun H. Bismuth-induced inactivation of ferric uptake regulator from Helicobacter pylori. Inorganic Chem. 2017;56:15041-8. doi: 10.1021/acs.inorgchem.7b02380
43. Nishizawa T, Nishizawa Y, Yahagi N, et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(Suppl.4):20-4. doi: 10.1111/jgh.12769
44. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41:1237-45. doi: 10.1111/apt.13214
45. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:97-107. doi: 10.1111/j.1523-5378.2009.00716.x
46. Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2009;29:720-30. doi: 10.1111/j.1365-2036.2009.03934.x
47. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Metaanalysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25:155-68. doi: 10.1111/j.1365-2036.2006.03179.x
48. Бордин Д.С., Войнован И.Н., Хомерики С.Г., Янова О.Б., Ким В.А., Быстровская Е.В., Шишин К.В. Эффективность и безопасность Lactobacillus Reuteri DSMZ17648 у инфицированных Helicobacter pylori. Лечащий врач. 2016;(5):106 [Bordin DS, Vojnovan IN, Homeriki SG, Yanova OB, Kim VA, Bystrovskaya ЕV, Shishin KV. Efficiency and safety of Lactobacillus reuteri DSMZ17648 in patients infected with Helicobacter pylori. Lechashchij Vrach. 2016;(5):106 (In Russ.)].
49. Hardbower DM, Peek RM Jr, Wilson KT. At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol. 2014;96(2):201-12. doi: 10.1189/jlb.4BT0214-099R
50. Niikura R, Hayakawa Y, Hirata Y, Ogura K, Fujishiro M, Yamada A, Ushiku T, Konishi M, Fukayama M, Koike K. The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion. Int J Mol Sci. 2019;20(8). pii: E1913. doi: 10.3390/ijms20081913
51. Ливзан М.А., Мозговой С.И., Кононов А.В. Гастрит после эрадикации Helicobacter pylori – простые следы или серьезные последствия? Лечащий врач. 2011;(7):7 [Livzan MA, Mozgovoj SI, Kononov AV. Gastritis after eradication of Helicobacter pylori – simple traces or serious consequences? Lechashchij Vrach. 2011;(7):7 (In Russ.)].
52. Ливзан М.А., Кононов А.В., Мозговой С.И. Постэрадикационный период хронического гастрита, ассоциированного с инфекцией Helicobacter pylori. Consilium Medicum. 2008;10(8):15-20 [Livzan MA, Kononov AV, Mozgovoj SI. Postradiation period of chronic gastritis associated with Helicobacter pylori infection. Consilium Medicum. 2008;10(8):15-20 (In Russ.)].
53. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. doi: 10.1136/bmj.g3174
54. Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708-16. doi: 10.1016/j.ejca.2006.01.020
55. Kalisperati P, Spanou E, Pateras IS et al. Inflammation, DNA Damage, Helicobacter pylori and Gastric Tumorigenesis. Front Genet. 2017;8:20. doi: 10.3389/fgene.2017.00020
56. Graham DY, Matsueda S, Shiotani A. Changing the natural history of metachronous gastric cancer after H. pylori eradication. Jpn J Helicobacter Res. 2015;16:42-50.
57. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004;157:301-11.
58. Demiray M, Gulten M, Manavoglu O et al. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study. Hepatogastroenterology. 2004;51(59):1531-5.
59. Кононов А.В., Ливзан М.А., Мозговой С.И. Гастрит после эрадикации: экс-геликобактерный или постэрадикационный? В кн.: Тезисы докладов Х Российского национального конгресса «Человек и лекарство». М., 2003 [Kononov AV, Livzan MA, Mozgovoy SI. Gastritis after eradication: ex-helicobacter or post-eradication? In: Tezisy dokladov X Rossiyskogo Natsional’nogo kongressa "Chelovek i lekarstvo" [Abstracts of the reports of the X Russian National Congress "Human and Medicine"]. Moscow, 2003 (In Russ.)].
60. Shimada M, Ina K, Kyokane K, et al. Upregulation of mucosal soluble fas ligand and interferon-gamma may be involved in ulcerogenesis in patients with Helicobacter pylori-positive gastric ulcer. Scand J Gastroenterol. 2002;37(5):501-11. doi: 10.1080/00365520252903026
61. Маев И.В. Современные представления о заболеваниях желудочно-кишечного тракта, ассоциированных с Helicobacter pylori. Терапевтический архив. 2006;78(2):10-5 [Maev IV. Current views on gastrointestinal diseases associated with Helicobacter pylori. Therapeutic Archive. 2006;78(2):10-5 (In Russ.)]. 
62. Osawa H, Kita H, Ohnishi H, Mutoh H, Ishino Y, Satoh K, Sugano K. Histamine-2 receptor expression in gastric mucosa before and after Helicobacter pylori cure. Aliment Pharmacol Ther. 2005;21(Suppl.2):92-8. doi: 10.1111/j.1365-2036.2005.02481.x
63. Cheung KS, Leung WK. Risk of gastric cancer development after eradication of Helicobacter pylori. World J Gastrointest Oncol. 2018;10(5):115-23. doi: 10.4251/wjgo.v10.i5.115
64. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-40. 
65. Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric Cancer. 2004;7:9-16. doi: 10.1007/s10120-003-0265-0
66. Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;91(8):4-12 [Maev IV, Samsonov AA, Andreev DN, Grechushnikov VB, Korovina TI. Clinical significance of Helicobacter pylori infection. Klinicheskaya Meditsina (Mosc). 2013;91(8):4-12 (In Russ.)].
67. Han X, Jiang K, Wang B, et al. Effect of Rebamipide on the Pre- malignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig. 2015;35(10):665-73. doi: 10.1007/s40261-015-0329-z
68. Tanigawa T, Pai R, Arakawa T, Tarnawski AS. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci. 2007;52(1):240-7. doi: 10.1007/s10620-006-9226-x
69. Tsukamoto H, Mizoshita T, Katano T, Hayashi N, Ozeki K, Ebi M, Shimura T, Mori Y, Tanida S, Kataoka H, Tsukamoto T, Tatematsu M, Joh T. Preventive effect of rebamipide on N-methyl-N’-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Exp Toxicol Pathol. 2015;67(3):271-7. doi: 10.1016/j.etp.2015.01.003
70. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9 [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
71. Андреев Д.Н., Маев И.В., Дичева Д.Т., Самсонов А.А., Парцваниа-Виноградова Е.В. Эффективность и безопасность применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori: проспективное рандомизированное сравнительное исследование. Терапевтический архив. 2018;90(8):27-32 [Andreev DN, Maev IV, Dicheva DT, Samsonov AA, Partzvania-Vinogradova EV. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Therapeutic Archive. 2018;90(8):27-32 (In Russ.)]. doi: 10.26442/terarkh201890827-32

________________________________________________

1. Maixner F, Krause-Kyora B, Turaev D, Herbig A, Hoopmann MR, Hallows JL, Kusebauch U, Vigl EE, Malfertheiner P, Megraud F, O'Sullivan N, Cipollini G, Coia V, Samadelli M, Engstrand L, Linz B, Moritz RL, Grimm R, Krause J4, Nebel A, Moodley Y, Rattei T, Zink A. The 5300-year-old Helicobacter pylori genome of the Iceman. Science. 2016;351(6269):162-5. doi: 10.1126/science.aad2545
2. Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomed J. 2016;39:14-23. doi: 10.1016/j.bj.2015.06.002
3. Schistosomes, liver flukes and Helicobacter pylori IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.
4.  [Maev IV, Bakulin IG, Kurilovich SA, Bakulina NV, Andreev NG, Golubev NN. Helicobacter pylori and extragastroduodenal diseases: the proven facts and assumptions. Dokazatel'naya Gastroenterologiya. 2018;7(3):45-59 (In Russ.)]. doi: 10.17116/dokgastro2018703145
5. Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter. 2015;20(Suppl 1):40-6. doi: 10.1111/hel.12256
6. Kountouras J, Polyzos SA, Katsinelos P, Zeglinas C, Artemaki F, Tzivras D, Vardaka E, Gavalas E, Romiopoulos I, Simeonidou C, Grigoriadis N, Kountouras C, Dardiotis E, Deretzi G. Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. Int J Cardiol. 2017;229:17-8. doi: 10.1016/j.ijcard.2016.11.265
7. Wang XL, Zeng J, Yang Y, Xiong Y, Zhang ZH, Qiu M, Yan X, Sun XY, Tuo QZ, Liu R, Wang JZ. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3β. J Alzheimers Dis. 2015;43:153-65. doi: 10.3233/JAD-140198
8. Ricci V, Romano M, Boquet P. Molecular cross-talk between Helicobacter pylori and human gastric mucosa. World J Gastroenterol. 2011;17(11):1383-99. doi: 10.3748/wjg.v17.i11.1383
9. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-67. doi: 10.1136/gutjnl-2015-309252
10. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelho LG, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh KL, Wong BC, Krabshuis J, Le Mair A, World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20:299-304.
11. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. doi: 10.1136/gutjnl-2016-312288
12. [Ivashkin VT, Mayev IV, Lapina TL, Sheptulin AA, Trukhmanov AS, Baranskaya YeK, Abdulkhakov RA, Alekseyeva OP, Alekseyenko SA, Dekhnich NN, Kozlov RS, Klyaritskaya IL, Korochanskaya N.V, Kurilovich SA, Osipenko MF, Simanenkov VI, Tkachev AV, Khlynov IB, Tsukanov VV. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2018;28(1):55-70 (In Russ.)].
13. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
14. Graham DY. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut. 2017;66:2043-6. doi: 10.1136/gutjnl-2017-314744
15. Zagari RM, Rabitti S, Eusebi LH, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest. 2018;48:e12857. doi: 10.1111/eci.12857
16.  [Bakulina NV, Simanenkov VI, Bakulin IG, Ilchishina TA. Prevalence of Helicobacter pylori infection among physicians. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2017;148(12):20-4 (In Russ.)].
17. Auttajaroon J, Chotivitayatarakorn P, Yamaoka Y, Vilaichone RK. CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection. Asian Pac J Cancer Prev. 2019;20(4):1243-7. doi: 10.31557/APJCP.2019.20.4.1243
18. [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
19. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-40. doi: 10.5829/idosi.wasj.2014.30.mett.61
20. Boltin D, Dotan I, Birkenfeld S. Improvement in the implementation of Helicobacter pylori management guidelines among primary care physicians following a targeted educational intervention. Ann Gastroenterol. 2019;32(1):52-9. doi: 10.20524/aog.2018.0329
21. Ribaldone D, Astegiano M, Pellicano R. Helicobacter pylori eradication: poor medical compliance from East to West of the world. Scand J Gastroenterol. 2018;53:265. doi: 10.1080/00365521.2018.1433231
22. [Osipenko MF, Livzan MA, Bikbulatova EA. Patient compliance as one of the factors determining the efficiency of eradication therapy. Therapeutic Archive. 2014;86(2):27-31 (In Russ.)].
23. O'Connor HJ. Helicobacter pylori and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits. Aliment Pharmacol Ther. 2002;16(3):487-96. doi: 10.1046/j.1365-2036.2002.01183.x
24. [Bordin D, Belousova N, Vorob'yova N, Zelenikin S. Ulcer disease: ways to increase the efficiency of Helicobacter pylori eradication. Vrach. 2011;(4):43-7 (In Russ.)].
25. Wang CH, Liao ST, Yang J, Li CX, Yang YY, Han R, Chen DF, Lan CH. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. World J Gastroenterol. 2015;21(39):11179-84. doi: 10.3748/wjg.v21.i39.11179
26. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitorbased triple therapy regimens: a meta-analysis of randomized clinical trials. Plos One. 2013;8:e62162. doi: 10.1371/journal.pone.0062162
27. [Elokhina EV, Kostenko MB, Livzan MA, Scalskiy SV. The effectiveness of eradication in patients with peptic ulcer disease associated with Helicobacter pylori, depending on the genotype of the drugmetabolism of proton pump inhibitors. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2015;115(3):31-3 (In Russ.)].
28. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868-77. doi: 10.1111/j.1365-2036.2008.03807.x
29. [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
30. Graham DY, Dore MP. Update on the use of vonoprazan: a competitive acid blocker. Gastroenterology. 2018;154:462-6. doi: 10.1053/j.gastro.2018.01.018
31. Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza I, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci. 2018;63:302-11. doi: 10.1007/s10620-017-4866-6
32. Kusunoki M, Yuki M, Ishitobi H, Kobayashi Y, Nagaoka M, Takahashi Y, Fukuba N, Komazawa Y, Shizuku T, Kinoshita Y. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication. Intern Med. 2019 Feb 1. doi: 10.2169/internalmedicine.2233-18
33. Sugimoto M, Yamaoka Y. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019;9:1560. doi: 10.3389/fphar.2018.01560
34. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304
35. Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potas- sium-Competitive Acid Blocker Compared With a 7-Day PPI- Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol. 2016;111(7):949-56. doi: 10.1038/ajg.2016.182
36. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-33. doi: 10.1111/apt.13497
37. Mégraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34-42. doi: 10.1136/gutjnl-2012-302254
38. Hu Y, Zhu Y, Lu NH. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 2017;7:168. doi: 10.3389/fcimb.2017.00168
39. Pellicano R, Zagari RM, Zhang S, Saracco GM, Moss SF. Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018;64:310-21. doi: 10.23736/S1121-421X.18.02492-3
40. [Bordin DS, Embutnieks YuV, Vologzhanina LG, et al. European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years. Therapeutic Archive. 2019;91(2):16-24 (In Russ.)]. doi: 10.26442/00403660.2019.02.000156
41. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318-27. doi: 10.1016/S1473-3099(17)30753-3
42. He X, Liao X, Li H, Xia W, Sun H. Bismuth-induced inactivation of ferric uptake regulator from Helicobacter pylori. Inorganic Chem. 2017;56:15041-8. doi: 10.1021/acs.inorgchem.7b02380
43. Nishizawa T, Nishizawa Y, Yahagi N, et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(Suppl.4):20-4. doi: 10.1111/jgh.12769
44. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41:1237-45. doi: 10.1111/apt.13214
45. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:97-107. doi: 10.1111/j.1523-5378.2009.00716.x
46. Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2009;29:720-30. doi: 10.1111/j.1365-2036.2009.03934.x
47. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Metaanalysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25:155-68. doi: 10.1111/j.1365-2036.2006.03179.x
48. [Bordin DS, Vojnovan IN, Homeriki SG, Yanova OB, Kim VA, Bystrovskaya ЕV, Shishin KV. Efficiency and safety of Lactobacillus reuteri DSMZ17648 in patients infected with Helicobacter pylori. Lechashchij Vrach. 2016;(5):106 (In Russ.)].
49. Hardbower DM, Peek RM Jr, Wilson KT. At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol. 2014;96(2):201-12. doi: 10.1189/jlb.4BT0214-099R
50. Niikura R, Hayakawa Y, Hirata Y, Ogura K, Fujishiro M, Yamada A, Ushiku T, Konishi M, Fukayama M, Koike K. The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion. Int J Mol Sci. 2019;20(8). pii: E1913. doi: 10.3390/ijms20081913
51. [Livzan MA, Mozgovoj SI, Kononov AV. Gastritis after eradication of Helicobacter pylori – simple traces or serious consequences? Lechashchij Vrach. 2011;(7):7 (In Russ.)].
52. [Livzan MA, Kononov AV, Mozgovoj SI. Postradiation period of chronic gastritis associated with Helicobacter pylori infection. Consilium Medicum. 2008;10(8):15-20 (In Russ.)].
53. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. doi: 10.1136/bmj.g3174
54. Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708-16. doi: 10.1016/j.ejca.2006.01.020
55. Kalisperati P, Spanou E, Pateras IS et al. Inflammation, DNA Damage, Helicobacter pylori and Gastric Tumorigenesis. Front Genet. 2017;8:20. doi: 10.3389/fgene.2017.00020
56. Graham DY, Matsueda S, Shiotani A. Changing the natural history of metachronous gastric cancer after H. pylori eradication. Jpn J Helicobacter Res. 2015;16:42-50.
57. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004;157:301-11.
58. Demiray M, Gulten M, Manavoglu O et al. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study. Hepatogastroenterology. 2004;51(59):1531-5.
59. [Kononov AV, Livzan MA, Mozgovoy SI. Gastritis after eradication: ex-helicobacter or post-eradication? In: Tezisy dokladov X Rossiyskogo Natsional’nogo kongressa "Chelovek i lekarstvo" [Abstracts of the reports of the X Russian National Congress "Human and Medicine"]. Moscow, 2003 (In Russ.)].
60. Shimada M, Ina K, Kyokane K, et al. Upregulation of mucosal soluble fas ligand and interferon-gamma may be involved in ulcerogenesis in patients with Helicobacter pylori-positive gastric ulcer. Scand J Gastroenterol. 2002;37(5):501-11. doi: 10.1080/00365520252903026
61.  [Maev IV. Current views on gastrointestinal diseases associated with Helicobacter pylori. Therapeutic Archive. 2006;78(2):10-5 (In Russ.)]. 
62. Osawa H, Kita H, Ohnishi H, Mutoh H, Ishino Y, Satoh K, Sugano K. Histamine-2 receptor expression in gastric mucosa before and after Helicobacter pylori cure. Aliment Pharmacol Ther. 2005;21(Suppl.2):92-8. doi: 10.1111/j.1365-2036.2005.02481.x
63. Cheung KS, Leung WK. Risk of gastric cancer development after eradication of Helicobacter pylori. World J Gastrointest Oncol. 2018;10(5):115-23. doi: 10.4251/wjgo.v10.i5.115
64. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-40. 
65. Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric Cancer. 2004;7:9-16. doi: 10.1007/s10120-003-0265-0
66.  [Maev IV, Samsonov AA, Andreev DN, Grechushnikov VB, Korovina TI. Clinical significance of Helicobacter pylori infection. Klinicheskaya Meditsina (Mosc). 2013;91(8):4-12 (In Russ.)].
67. Han X, Jiang K, Wang B, et al. Effect of Rebamipide on the Pre- malignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig. 2015;35(10):665-73. doi: 10.1007/s40261-015-0329-z
68. Tanigawa T, Pai R, Arakawa T, Tarnawski AS. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci. 2007;52(1):240-7. doi: 10.1007/s10620-006-9226-x
69. Tsukamoto H, Mizoshita T, Katano T, Hayashi N, Ozeki K, Ebi M, Shimura T, Mori Y, Tanida S, Kataoka H, Tsukamoto T, Tatematsu M, Joh T. Preventive effect of rebamipide on N-methyl-N’-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Exp Toxicol Pathol. 2015;67(3):271-7. doi: 10.1016/j.etp.2015.01.003
70. [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Therapeutic Archive. 2014;86(3):94-9 (In Russ.)].
71.  [Andreev DN, Maev IV, Dicheva DT, Samsonov AA, Partzvania-Vinogradova EV. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Therapeutic Archive. 2018;90(8):27-32 (In Russ.)]. doi: 10.26442/terarkh201890827-32

М.А. Ливзан 

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия

________________________________________________

M.A. Livzan

Omsk State Medical University, Omsk, Russia